Skip to main content
Signal8

Zura Bio Ltd (ZURA)

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Zura Bio Limited logo

Zura Bio Limited

NASDAQ:ZURAHealthcare
AH-0.48%$1.03
Close$1.03-4.17%
Mkt Cap$99.7M
EV-
Float68.65M
O/S96.33M
VOL3.52M sh
$ Vol$3.58M
RVOL0.47×
Inst Own71.9%
Net Cash/Sh-
EarningsMar 31 · in 4mo
Dilution
Zura Bio Limited logoNASDAQ:ZURAAH$1.03-0.48%

Zura Bio Ltd (ZURA) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 43 SEC filings.

Shelf registration
S-3 filed Oct 27, 2026, effective Nov 3, 2026
Source: EFFECT filed Nov 3, 2026
At-the-market (ATM) program
Yes, sales agreement dated Sep 3, 2024
Source: EFFECT filed Nov 3, 2026
Warrants outstanding
5 warrant series recorded as outstanding
Most recent offering
Public offering, priced Feb 24, 2026
Source: 10-Q filed Oct 27, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro